|
Gene: WDR17 |
Gene summary for WDR17 |
Gene summary. |
Gene information | Species | Human | Gene symbol | WDR17 | Gene ID | 116966 |
Gene name | WD repeat domain 17 | |
Gene Alias | WDR17 | |
Cytomap | 4q34.2 | |
Gene Type | protein-coding | GO ID | NA | UniProtAcc | Q8IZU2 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
116966 | WDR17 | HCC1 | Human | Liver | HCC | 5.09e-09 | 8.86e-01 | 0.5336 |
116966 | WDR17 | HCC2 | Human | Liver | HCC | 1.41e-14 | 1.01e+00 | 0.5341 |
116966 | WDR17 | HCC5 | Human | Liver | HCC | 3.01e-14 | 8.14e-01 | 0.4932 |
116966 | WDR17 | HTA12-23-1 | Human | Pancreas | PDAC | 1.27e-03 | 6.03e-01 | 0.3405 |
116966 | WDR17 | HTA12-25-1 | Human | Pancreas | PDAC | 3.33e-03 | 4.07e-01 | 0.313 |
116966 | WDR17 | HTA12-26-1 | Human | Pancreas | PDAC | 2.63e-13 | 7.33e-01 | 0.3728 |
116966 | WDR17 | HTA12-29-1 | Human | Pancreas | PDAC | 9.44e-28 | 6.40e-01 | 0.3722 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Liver | HCC: Hepatocellular carcinoma | |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
WDR17 | SNV | Missense_Mutation | rs752508228 | c.3539T>C | p.Ile1180Thr | p.I1180T | Q8IZU2 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
WDR17 | SNV | Missense_Mutation | c.907N>G | p.Thr303Ala | p.T303A | Q8IZU2 | protein_coding | tolerated(0.1) | benign(0.015) | TCGA-A5-A0VQ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD | |
WDR17 | SNV | Missense_Mutation | rs200278729 | c.2648N>A | p.Cys883Tyr | p.C883Y | Q8IZU2 | protein_coding | tolerated(0.43) | probably_damaging(0.996) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
WDR17 | SNV | Missense_Mutation | novel | c.1336N>T | p.Pro446Ser | p.P446S | Q8IZU2 | protein_coding | deleterious(0.02) | benign(0.437) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
WDR17 | SNV | Missense_Mutation | c.2516N>G | p.Met839Arg | p.M839R | Q8IZU2 | protein_coding | deleterious(0) | probably_damaging(0.972) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR | |
WDR17 | SNV | Missense_Mutation | c.292N>A | p.Leu98Met | p.L98M | Q8IZU2 | protein_coding | tolerated(0.1) | benign(0.065) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
WDR17 | SNV | Missense_Mutation | novel | c.2525N>G | p.Leu842Arg | p.L842R | Q8IZU2 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
WDR17 | SNV | Missense_Mutation | novel | c.3805N>A | p.His1269Asn | p.H1269N | Q8IZU2 | protein_coding | deleterious(0.01) | benign(0.445) | TCGA-AJ-A3TW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
WDR17 | SNV | Missense_Mutation | c.3001G>T | p.Ala1001Ser | p.A1001S | Q8IZU2 | protein_coding | tolerated(0.6) | benign(0.003) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
WDR17 | SNV | Missense_Mutation | novel | c.3209N>G | p.Leu1070Arg | p.L1070R | Q8IZU2 | protein_coding | deleterious(0) | probably_damaging(0.914) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |